Efficacy and Systemic Safety of Netarsudil 0.01%, 0.02%, 0.04% Relative to Placebo in Subjects With Open-angle Glaucoma or Ocular Hypertension in Japan

Sponsor
Aerie Pharmaceuticals
Study ID
NCT03844945
Phase
PHASE2
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
20 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

Test ocular hypotensive efficacy and systemic safety of netarsudil 0.01%, 0.02%, 0.04% relative to placebo in subjects with open-angle glaucoma or ocular hypertension in Japan

Key Dates

Start date
Mar 19, 2019
Status verified
Sep 2020
Primary completion
Sep 19, 2019
Completion
Sep 19, 2019

Study Design

Enrollment
215 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Netarsudil Ophthalmic Solution 0.01%
    1 drop daily into each eye in the evening for 28 days
  • Experimental: Netarsudil Ophthalmic Solution 0.02%
    1 drop daily into each eye in the evening for 28 days
  • Experimental: Netarsudil Ophthalmic Solution 0.04%
    1 drop daily into each eye in the evening for 28 days
  • Placebo Comparator: Netarsudil Ophthalmic Solution Placebo
    1 drop daily into each eye in the evening for 28 days

Primary Outcome Measure

Intraocular Pressure (IOP) [ Time Frame: 29 Days ]

Related Studies